Back

Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Secondary prevention (2) Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Cesar Jimenez Mendez

Puerta del Mar University Hospital, Cadiz (Spain)

7 More presentations in this session

Presentation thumbnail
The influence of medication costs on secondary cardiovascular prevention decisions: two discrete choice experiments among patients and prescribers
Miss E. Wempe (NL)
Abstract Slides Video
Presentation thumbnail
Low molecular weight heparin for AMI with frailty: short-Term outcomes after early PCI
Professor K. Chen (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
COVID-19 vaccination confers long-term cardioprotection against post-COVID cardiovascular disease: >5-year evidence from causal mediation and target trial emulation
Mr B. Seboka (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
The German lipoprotein apheresis registry - summary of the thirteenth annual report
Doctor A. Vogt (Munich, DE)
Abstract Slides Video
Presentation thumbnail
The newest pillar is the most fragile: SGLT2 inhibitors show the lowest 12-month ongoing use among guideline-directed CAD medications in a 15-country European survey
Mr L. Kieviet (Utrecht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Inflammatory risk in patients with coronary artery disease: the impact of cardiac rehabilitation and association to cardiorespiratory fitness
23 April 2026
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025
thumbnail
Congress Presentation
Inflammation in obesity-related HFpEF: the STEP-HFpEF programme
30 August 2024
thumbnail
Congress Presentation
Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources